Last reviewed · How we verify

NCT03362580

Prevalence and Risk Factors of Epiretinal Membrane in Diabetic and Non-diabetic Patients

Completed Last updated 9 July 2020
What this trial tests

trial testing Slit lamp examination in Epiretinal Membrane in 200 participants. Completed in 10 October 2019.

Timeline
12 December 2017
Primary endpoint
10 October 2019
10 October 2019

Quick facts

Lead sponsorLaurence Postelmans
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date12 December 2017
Primary completion10 October 2019
Estimated completion10 October 2019
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Laurence Postelmans

Who can join

15 and older, any sex, with Epiretinal Membrane. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Numerous terms have been used to describe epiretinal membrane (ERM): macular pucker, epimacular membrane, surface-wrinkling retinopathy, cellophane maculopathy and preretinal macular fibrosis. It is, by definition, a fibrocellular tissue found on the inner surface of the retina. It is semi-translucent and proliferates on or above the surface of the internal limiting membrane. It causes blurring and metamorphopsia, while mild cases are often asymptomatic. ERM presence can degrade the acuity and the quality of vision, thus affecting the quality of life. There is evidence that it also has an adverse impact to the treatment options for patients suffering from macular disorders. More specifically, regarding to diabetic retinopathy, ERM seems to have a bidirectional etiopathogenetic relationship with its course and complications. The aim of this study is to know the prevalence of ERM in the Brussel's population, the risk factors predisposing to ERM formation and if diabetic patients have a significantly higher prevalence of ERM in comparison to general population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Slit lamp examination

Trials testing the same drug.

Other recruiting trials for Epiretinal Membrane

Currently open trials in the same condition.

Other Laurence Postelmans trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03362580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing